Ignite Creation Date:
2025-12-25 @ 4:32 AM
Ignite Modification Date:
2026-03-02 @ 4:10 AM
Study NCT ID:
NCT02641418
Status:
COMPLETED
Last Update Posted:
2019-07-31
First Post:
2015-08-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Optimising the Efficacy, Patient Perception and Uptake of an Exercise Programme in People in Intermittent Claudication
Sponsor:
Hull University Teaching Hospitals NHS Trust
Organization:
Study Overview
Official Title:
Optimising the Efficacy, Patient Perception and Uptake of an Exercise Programme in People in Intermittent Claudication
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SEIC
Brief Summary:
Background: Peripheral arterial disease is a result of atherosclerotic occlusion in the major arteries supplying the lower limbs and is associated with an increased risk of mortality and morbidity. It results in restricted blood flow to the skeletal muscles causing intermittent claudication (IC). IC presents as cramp like pain affecting 5% of the population \>50 years and is associated with a substantial reduction in walking capacity, quality of life and diminished physical function. Supervised exercise programmes have been demonstrated to improve maximum walking distances and NICE recommends group-based supervised exercise for treating patients with IC. However, there is significant variability in the impact of treatment across studies and little agreement on the underlying mechanism whereby exercise increases functional outcomes. Potential mechanisms include skeletal muscle metabolism, VO2 max, anaerobic threshold and endothelial function. Studies are needed to better understand how exercise improves outcome and in whom, so as to better refine and target the treatment.
The participation of patients with IC in exercise programmes is low. The investigators need to understand factors influencing participation so that we can improve the number of patients with IC benefiting from the programme
The research consists of two workstreams:
Workstream one
Objective:
Assess the extent to which patient baseline characteristics and candidate physiological mechanisms are associated with clinical improvement in IC patients participating in an exercise programme
Patients: Patients with documented IC referred from a Vascular Consultant. Eligible patients will be invited to participate in a 12 week supervised exercise programme.
Testing Schedule: Measurements will be recorded at baseline (prior to exercise), immediately after the completion of the exercise programme and then three months after. Measurements include:
Baseline characteristics that might predict outcome:
* Quality of life using the VascuQol questionnaire
* Clinical indicators of lower limb function: Ankle brachial pressure index (ABPI), intermittent claudication distance (ICD), Maximum walking distance (MWD).
Candidate physiological mechanisms
* Aerobic capacity (VO2 max \& AT)
* Muscular strength and endurance
* Muscle morphology (including muscle thickness, pennation angle, fascicle length and elastography)
* Endothelial function (sheer stress response as measured by flow mediated dilation)
Analysis: Regression analysis will be used to explain variation in patient maximum walking distance at 3 months. The regression will use 9 candidate measures of physiological response and 3 baseline measures to explore what mechanism and patient factors may be associated with clinical improvements. 100 patients recruited over 2 years will give a 90% power to detect an additional increase in variability in MWD explained by each candidate measure of around 5% at the a 0.05 significance level.
This research will be used to identify which types of exercise may be most influential in improving outcome and in which patients.
Workstream two
Objective:
Explore the reasons behind patients' participation, non-participation in, experience of and adherence to the exercise programme.
Study Design: An interview study of patients with IC routinely referred for supervised exercise. Three groups of patients will be invited to participate. Those who:
* Choose not to participate in the exercise programme (Group A)
* Agree to participate in the exercise programme (Group B).
* Agree to participate but discontinue after at least one session (Group C).
Semi-structured face-to-face interviews with 20 patients per group, interviews will be conducted using a topic guide to ensure consistency. The format will be flexible to allow participants to generate naturalistic data on what they consider as important and / or successful in terms of outcome. Data will be analysed thematically and managed using Nvivo software - the approach will be inductive and iterative.
This research will be used to redesign the current exercise programme to improve participation and so the impact of exercise in patients with IC.
The participation of patients with IC in exercise programmes is low. The investigators need to understand factors influencing participation so that we can improve the number of patients with IC benefiting from the programme
The research consists of two workstreams:
Workstream one
Objective:
Assess the extent to which patient baseline characteristics and candidate physiological mechanisms are associated with clinical improvement in IC patients participating in an exercise programme
Patients: Patients with documented IC referred from a Vascular Consultant. Eligible patients will be invited to participate in a 12 week supervised exercise programme.
Testing Schedule: Measurements will be recorded at baseline (prior to exercise), immediately after the completion of the exercise programme and then three months after. Measurements include:
Baseline characteristics that might predict outcome:
* Quality of life using the VascuQol questionnaire
* Clinical indicators of lower limb function: Ankle brachial pressure index (ABPI), intermittent claudication distance (ICD), Maximum walking distance (MWD).
Candidate physiological mechanisms
* Aerobic capacity (VO2 max \& AT)
* Muscular strength and endurance
* Muscle morphology (including muscle thickness, pennation angle, fascicle length and elastography)
* Endothelial function (sheer stress response as measured by flow mediated dilation)
Analysis: Regression analysis will be used to explain variation in patient maximum walking distance at 3 months. The regression will use 9 candidate measures of physiological response and 3 baseline measures to explore what mechanism and patient factors may be associated with clinical improvements. 100 patients recruited over 2 years will give a 90% power to detect an additional increase in variability in MWD explained by each candidate measure of around 5% at the a 0.05 significance level.
This research will be used to identify which types of exercise may be most influential in improving outcome and in which patients.
Workstream two
Objective:
Explore the reasons behind patients' participation, non-participation in, experience of and adherence to the exercise programme.
Study Design: An interview study of patients with IC routinely referred for supervised exercise. Three groups of patients will be invited to participate. Those who:
* Choose not to participate in the exercise programme (Group A)
* Agree to participate in the exercise programme (Group B).
* Agree to participate but discontinue after at least one session (Group C).
Semi-structured face-to-face interviews with 20 patients per group, interviews will be conducted using a topic guide to ensure consistency. The format will be flexible to allow participants to generate naturalistic data on what they consider as important and / or successful in terms of outcome. Data will be analysed thematically and managed using Nvivo software - the approach will be inductive and iterative.
This research will be used to redesign the current exercise programme to improve participation and so the impact of exercise in patients with IC.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: